|
Press Releases |
|
|
|
Wednesday, September 6, 2017 |
|
雅各臣發行5億港元可換股票據予Dragons 615 Limited及HH InRe JP, Ltd. |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)建議按一般授權發行二零二零年到期、本金總額5億港元的可換股票據予兩名認購人,分別為Dragons 615 Limited (「Dragons」,DCP China Credit Fund I, L.P. (「DCP Fund」)之全資擁有的有限公司)及HH InRe JP, Ltd. (「HH JP」,一間由Hillhouse InRe Fund, L.P.間接全資擁有的有限公司)。 more info >> |
|
Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd. |
Jacobson Pharma Corporation Limited , a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has proposed to issue Convertible Notes under general mandate, in an aggregate principal amount of HK$500 million due in 2020, to two subscribers namely Dragons 615 Limited and HH InRe JP, Ltd. more info >> |
|
Sunday, June 25, 2017 |
|
雅各臣公布二零一七年全年业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633)今天公布公司及附属公司(统称「集团」)截至二零一七年三月三十一日止年度(「二零一七财年」)的全年业绩,亦是公司在去年九月于香港上市后的首份全年业绩。 more info >> |
|
雅各臣公佈二零一七年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633)今天公佈公司及附屬公司(統稱「集團」)截至二零一七年三月三十一日止年度(「二零一七財年」)的全年業績,亦是公司在去年九月於香港上市後的首份全年業績。 more info >> |
|
Jacobson Pharma Announces 2017 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2017 ( "FY 2017" ). more info >> |
|
Wednesday, April 26, 2017 |
|
香港李众胜堂保济丸与「水滴无界」签订合作协议 |
李众胜堂(集团)有限公司(「李众胜堂」或「公司」)今天出席「水滴无界」于北京的上线启动仪式,并由代表与「水滴无界」签订合作协议,正式标志着双方展开于中国大陆市场携手合作的新里程。 more info >> |
|
香港李眾勝堂保濟丸與「水滴無界」簽訂合作協議 |
李眾勝堂(集團)有限公司(「李眾勝堂」或「公司」)今天出席「水滴無界」於北京的上線啟動儀式,並由代表與「水滴無界」簽訂合作協議,正式標誌著雙方展開於中國大陸市場攜手合作的新里程。 more info >> |
|
Monday, March 13, 2017 |
|
雅各臣公布收购康宁行70%权益 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业-雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布收购康宁行集团(包括「康宁行有限公司」及其香港附属公司)的70%权益,总代价为56,000,000港元。 more info >> |
|
雅各臣公布收購康寧行70%權益 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業-雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈收購康寧行集團(包括「康寧行有限公司」及其香港附屬公司)的70%權益,總代價為56,000,000港元。完成收購後,康寧行集團將成為雅各臣間接非全資附屬公司。 more info >> |
|
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 26, 2024 21:10 HKT/SGT
|
|
|
汇聚科技有限公司公布截至二零二三年十二月三十一日止末期业绩
Apr 26, 2024 18:53 HKT/SGT
|
|
|
匯聚科技有限公司公佈截至二零二三年十二月三十一日止末期業績
Apr 26, 2024 18:43 HKT/SGT
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023
Apr 26, 2024 18:26 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
可持续发展三大支柱引领 海通恒信ESG必答卷高分亮相
Apr 26, 2024 15:28 HKT/SGT
|
|
|
可持續發展三大支柱引領 海通恆信ESG必答卷高分亮相
Apr 26, 2024 15:25 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 14:34: JST
|
|
|
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について
Apr 26, 2024 14:00: JST
|
|
|
中滙集團公佈2024財年中期業績
Apr 26, 2024 13:51 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Interim Results
Apr 26, 2024 13:43 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 13:27 HKT/SGT
|
|
|
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting
Apr 26, 2024 13:16 HKT/SGT
|
|
|
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
|
|
|
|
More News >> |
|
|
|
|
|